The role of the physiotherapist in quantifying movement fluctuations in Parkinson's disease

Australian Journal of Physiotherapy

Volumn 44, Issue 2, 1998, Pages 105-107

  Morris, Meg ^a,b   Iansek, Robert ^a,c   Churchyard, Andrew ^a  

^a Kingston Centre   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Medication systems; Movement disorders; Parkinson disease; Physical therapy

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE MESILATE; BIPERIDEN; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; MESYLIC ACID; MONOAMINE OXIDASE B INHIBITOR; ORPHENADRINE; PERGOLIDE; PROCYCLIDINE; SELEGILINE; TRIHEXYPHENIDYL;

ANKLE EDEMA; ARTICLE; COGNITIVE DEFECT; CONFUSION; DRUG MONITORING; HALLUCINATION; HUMAN; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSICAL CAPACITY; PHYSIOTHERAPIST; VERTIGO; VISUAL DISORDER; VOMITING; XEROSTOMIA;

EID: 0031801148     PISSN: 00049514     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0004-9514(14)60370-6     Document Type: Article

References (49)

1. Alexander GE and Crutcher MD (1990): Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends in Neuroscience 13: 266-271.
2. Baas H, Stecker K and Fischer PA (1993): Value and appropriate use of rating scales and comparative measurements in quantification of disability in Parkinson's disease. Journal of Neural Transmission 5: 45-61.
3. Canning CG, Alison JA, Allen NE and Groeller H (1997): Parkinson's disease: an investigation of exercise capacity, respiratory function and gait. Archives of Physical Medicine and Rehabilitation 78: 199-207.
4. Canter R, de la Torre R, Mier M (1961): Amethod for evaluating disability in patients with Parkinson's disease. Journal of Nervous and Mental Diseases 133: 143-147.
5. Cotzias GC, Papavasiliou PS and Gellene R (1969): Modification of Parkinsonism - chronic treatment with L-dopa. New England Journal of Medicine 280: 337-345.
6. DeLong MR (1993): Overview of basal ganglia function. In Mano N, Hamada I, DeLong MR (Eds): Role of the Cerebellum and Basal Ganglia in Voluntary Movement. Amsterdam: Elsevier, pp. 65-70.
7. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E and Chase TN (1988): Motor fluctuations in Parkinson's disease: central physiological mechanisms, Part 1. Annals of Neurology 24: 366-371.
8. Fahn S, Marsden CD, Calne D and Goldstein M (1987): Recent Developments in Parkinson's Disease. New Jersey: MacMillan Healthcare.
9. Fix A and Daughton D (1988): Human Activity Profile Professional Manual. New York: Psychological Assessment Resources.
10. Gancher et al (1988): Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology 38: 12-716.
11. Godwin-Austen RB, Tomlinson EB, Frears CC and Kok HWL (1969): Effects of L-dopa in Parkinson's disease Lancet 2: 165-168.
12. Granger CV, Hamilton BB, Keith RA, Zielezny M and Sherwin FS (1986): Advances in functional assessment for medical rehabilitation. Topics in Geriatric Rehabilitation 3: 59-74.
13. Hamdorf P, Withers R, Penhall R and Haslam M (1992): Physical training effects on the fitness and habitual activity patterns of elderly women. Archives of Physical Medicine and Rehabilitation 73: 603-608.
14. Hamilton BB, Granger CV (1994): Disability outcomes following inpatient rehabilitation for stroke. Physical Therapy 74: 494-503.
15. Hill K, Bernhardt J, McGann A, Maltese D and Berkovitis D (1996a): A new test of dynamic standing balance for stroke patients: reliability, validity and comparison with healthy elderly. Physiotherapy Canada 48: 257-262.
16. Hill K, Schwartz J, Kalogeropoulos A and Gibson S (1996b): Fear of falling revisited. Archives of Physical Medicine and Rehabilitation 77: 1025-1029.
17. Hoehn MM, Yahr MD (1967): Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
18. Iansek R, Bradshaw J, Phillips J, Cunnington R and Morris ME (1995): Interaction of the basal ganglia and supplementary motor area in the elaboration of movement. In Glencross D and Piek J (Eds): Motor Control and Sensorimotor Integration. Elsevier: Amsterdam, pp. 37-59.
19. Iansek R, Morris ME, Kirkwood B (1997): Introduction. In Morris ME and Iansek R (Eds): Parkinson's Disease: A Team Approach. Melbourne: Buscombe Vicprint, pp. 1-12.
20. Jankovic J and Marsden CD (1988): Therapeutic strategies in Parkinson's disease. In Jankovic J and Tolosa E (Eds): Parkinson's Disease and Movement Disorders. Munich: Urban and Schwarzenberg.
21. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ and Stern GM (1989): Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. Journal of Neurology, Neurosuergery and Psychiatry 52: 718-723.
22. Kennard C, Munro AJ and Park DM (1984): The reliability of clinical assessment of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 47: 322-323.
23. Kidd D, Stewart G, Baldry J, Johnson J, Rossiter D, Petruckevitch A and Thompson A (1995): The Functional Independence Measure: a comparative validity and reliability study. Disability and Rehabilitation 17: 10-14.
24. Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. British Medical Journal 311: 1602-1607.
25. Marsden CD and ParkesJD (1976): "On-off effects" in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1: 292-296.
26. Metman LV, Locatelli ER, Bravi D, Mouradian MM and Chase TN (1997): Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48: 369-372.
27. Montgomery GK, Reynolds NC and Warren RM (1985): Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clinical Neuropharmacology 8: 83-92.
28. Morris ME, Iansek R, Matyas TA and Summers JJ (1994): The pathogenesis of gait hypokinesia in Parkinson's disease. Brain 117: 1161-1182.
29. Morris ME, Matyas TA, Summers JJ and Iansek R (1996a): Temporal stability of gait in Parkinson's disease. Physical Therapy 76: 763-777.
30. Morris ME, Iansek R, Matyas TA and Summers JJ (1996b): Stride length regulation in Parkinson's disease: Normalization strategies and underlying mechanisms. Brain 119: 551-568.
31. Morris ME and Iansek R (1997): Gait disorders in Parkinson's disease: a framework for physical therapy practice. Neurology Report 21: 125-131.
32. Mouradin MM and Chase TN (1994): Improved dopaminergic therapy of Parkinson's disease. In Marsden CD and Fahn S (Eds): Movement Disorders 3. Oxford: Butterworth Heinemann, pp. 180-199.
33. Nutt JG (1987): On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Annals of Neurology 22: 535-540.
34. Nutt JG, Woodward WR, Carter JH and Gancher ST (1992): Effect of long-term therapy on the pharmacodynamics of levodopa. Archives of Neurology 49: 1123-1130.
35. Pastor MA, Day BL and Marsden CD (1993) Vestibular induced postural responses in Parkinson's disease. Brain 116: 1177-1190.
36. Quattrone A, Zappia M, Aguglia U, Branca D, Colao R, Montesanti R, Nicoletti G, Palmieri A, Parlato G and Rizzo M (1995): The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Annals of Neurology 38: 389-395.
37. Podsialdo D and Richardson S (1991): The timed "Up & Go": a test of basic functional mobility for frail elderly persons. Journal of the American Geriatric Society 39: 142-148.
38. Reynolds EF (1996): Martindale: The Extra Pharmacopeia. (31st ed.) London: The Pharmaceutical Press.
39. Rinne UK (1989): Early dopamine agonist therapy in Parkinson's disease. Movement Disorders 4 (Suppl. 1): 86-94.
40. Schenkman M (1997) Reliability of impairment and physical performance measures for persons with Parkinson's disease. Physical Therapy 77: 19-27.
41. Schwab RS (1960): Progression and prognosis in Parkinson's disease. Journal of Nervous and Mental Disorders 130: 556-566.
42. Shoenberg BS (1987): Epidemiology of movement disorders. In Marsden CD and Fahn S (Eds): Movement Disorders 2. London: Butterworth, pp. 17-32.
43. Smithson F, Morris ME and Iansek (1998): Performance on clinical tests of balance in Parkinson's disease. Physical Therapy .
44. Soliveri P, Brown JR, Jahanshahi M and Marsden CD (1992): Effects of practice on performance of a skilled motor task in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 55: 454-460.
45. Tiffin J (1979): Purdue pegboard examiner manual. Lafayette Instruments Company, Reorder No.7-435. Lafayette 2.
46. Walker JE, Albers JW, Tourtellotte WW, Henderson WG, Potvin AR and Smith A (1972): A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. Journal of Chronic Diseases 25: 149-182.
47. Webster DD (1968): Critical analysis of the disability in Parkinson's disease. Modern Treatment 5: 257-282.
48. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE and Hoehn MM (1969): Treatment of parkinsonism with levodopa. Archives of Neurology 21: 343-354.
49. Youdim MBH and Riederer P (1997): Understanding Parkinson's disease. Scientific American January: 38-45.